All In Biotech

Drug Trial Radar · NCT03199586

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Dec 21, 2017

Primary completion

May 7, 2020

Study completion May 7, 2020

Sponsor

Lead sponsor
Novita Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Translational Drug Development
First posted
Jun 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.

Conditions

  • Breast Cancer
  • Pancreas Cancer
  • Prostate Cancer
  • Lung Cancer
  • Colon Cancer
  • Esophagus Cancer
  • Liver Cancer
  • Ovary Cancer
  • Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies

Interventions

  • NP-G2-044Drug

    capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Establish the safe recommended phase 2 doseTime frame: 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • Memorial Sloan Kettering Hospital

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.